<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Veradermics, Incorporated — News on 6ix</title>
    <link>https://6ix.com/company/veradermics-incorporated</link>
    <description>Latest news and press releases for Veradermics, Incorporated on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Sun, 26 Apr 2026 20:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/veradermics-incorporated" rel="self" type="application/rss+xml" />
    <item>
      <title>Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss</title>
      <link>https://6ix.com/company/veradermics-incorporated/news/veradermics-to-hold-conference-call-to-discuss-topline-results-from-phase-23-302-study-of-vdphl01-in-males-with-mild-to-moderate-pattern-hair-loss</link>
      <guid isPermaLink="true">https://6ix.com/company/veradermics-incorporated/news/veradermics-to-hold-conference-call-to-discuss-topline-results-from-phase-23-302-study-of-vdphl01-in-males-with-mild-to-moderate-pattern-hair-loss</guid>
      <pubDate>Sun, 26 Apr 2026 20:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., April 26, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast to review topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 ‘302’ clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males with mild-to-moderate patter</description>
    </item>
  </channel>
</rss>